Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent increase in revenues to $5.71 billion. Protonix sales fell 66 percent, but revenues from the arthritis treatment Enbrel skyrocketed by 36 percent. Report